Healthy individuals and individuals with spasticity Signs and Symptoms
Conditions
Interventions
Healthy volunteers are involved in a double-blinded placebo-controlled cross-over study. All subjects receive either nimodipine (60mg) or baclofen (25mg) on the first experimental day. All subjects re
Sponsors
University of Copenhagen
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 years old and over 2. Adults capable of providing informed consent for participation 3. Healthy volunteers will be recruited in the first part of the project 4. In the second part of the project, individuals with symptoms of muscle overactivity (spasticity/spasms/cramps/dystonia) due to CNS damage are recruited
Exclusion criteria
Exclusion criteria: 1. Hypotension (systolic blood pressure <100mmHg) 2. Known impaired liver function, cerebral edema, or significantly increased intracranial pressure 3. Antispastic medication that cannot be paused, or recent botox injections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H/M-ratio measured using surface electromyographic (EMG) analysis of soleus muscle activity before and at 30, 60 and 90 minutes after intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures are measures using surface EMG before and at 30, 60 and 90 minutes after the intervention: 1. The size of the stretch reflex during rest and voluntary pre-contraction measured using surface EMG 2. The size of the cutaneous reflex measured using surface EMG from m. tibialis anterior and m. soleus | — |
Countries
Denmark
Contacts
Public ContactEva Rudjord Therkildsen
Outcome results
None listed